Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by Wino115


T.TH

RE:RE:RE:RE:RE:RE:RE:RE:MTD

I think you are reading way to much into that as what that colloquialism...

March 15, 2022

T.TH

RE:RE:RE:RE:RE:RE:MTD

Perhaps the most interesting tract from your meeting is that they are not...

March 15, 2022

T.TH

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Pre-Clinical only!

I recall the Sortina Pharma/Univ Gotenburg team, who are quite a way behind...

March 10, 2022

T.TH

RE:DLT window versus evaluation window

It's complicated, but this makes sense to me in understanding the huge...

March 5, 2022

T.TH

RE:RE:RE:RE:RE:RE:Bad choice...

Thank you for bringing in the human element here - the most important part of...

March 3, 2022

T.TH

RE:RE:Bad choice...

I would say this board is generally highly informed about the key issues. So...

March 2, 2022

T.TH

Bad choice...

Looks like CEO and Board should have waited for the option grants which...

March 2, 2022

T.TH

RE:RE:RE:RE:RE:RE:RE:RE:Very difficult to be constructive

Given they expanded the board way more than they needed but did not pull...

March 2, 2022

T.TH

From 2021 AACR Poster = mouse studies ALL equivalent doses

" * TH1902 demonstrated better and sustained efficacy at doses...

February 27, 2022

T.TH

RE:RE:RE:RE:RE:RE:RE:RE:RE:Any comments on this from Leede's Doug Loe?

Sorry JFM, I believe you are wrong on this.  Take a look at this chart...

February 26, 2022

T.TH

RE:RE:RE:RE:RE:RE:Any comments on this from Leede's Doug Loe?

I wouldn't disagree with your overall view that they didn't give...

February 25, 2022

T.TH

RE:RE:RE:RE:Any comments on this from Leede's Doug Loe?

On the AEs, in reading a lot of trial PRs, I noticed that certain types of...

February 25, 2022

T.TH

RE:Any comments on this from Leede's Doug Loe?

I belive one of our science experts once discussed how to convert what the...

February 25, 2022

T.TH

RE:RE:RE:RE:RE:RE:RE:Disapointed and mostly in the dark.

I wouldn't disagree, but the more 8mportant thing is whether the concept...

February 24, 2022

T.TH

RE:RE:RE:Quick Summary

I think there's a chart in one of their poster presentations showing how...

February 24, 2022

T.TH

RE:AGM

It will make for another interesting meeting, but Soleus is in control of...

February 24, 2022

T.TH

RE:RE:RE:Did it move tail risks?

A few other intriguing points were hinted at.  First off, in the...

February 24, 2022

T.TH

Did it move tail risks?

To me, I just want to make sure they're putting TH1902 in a position to...

February 24, 2022

T.TH

RE:RE:2022 Business Objectives—-

Not sure how you reach that conclusion. The future is pretty clearly using...

February 24, 2022

T.TH

RE:RE:Seens that MTD will be 300

I figure it's the more typical AEs you see and the view was to move down,...

February 24, 2022

Featured Company